Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

By Swaisland H.  

Clinical Pharmacokinetics, Vol. 40, Iss. 4, 2001-01 ,pp. : 297-306

Adis International

Access to resources Recommend Favorite

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3896-3901

Blackwell Publishing

Access to resources Recommend Favorite

A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

By MacKenzie Mary   Hirte Holger   Glenwood Goss   Jean Maroun   Goel Rakesh   Major Pierre   Miller Jr. Wilson   Panasci Lawrence   Lorimer Ian   Batist Gerald   Matthews Sarah   Douglas Lynn   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 165-170

Springer Publishing Company

Access to resources Recommend Favorite

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

By  

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

By Li Jing   Brahmer Julie   Messersmith Wells   Hidalgo Manuel   Baker Sharyn  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite